
The Peter Attia Drive #112 - Ned David, Ph.D.: How cellular senescence influences aging, and what we can do about it
Jun 1, 2020
Ned David, co-founder of Unity Biotechnology and a PhD from Cal Berkeley, dives deep into the science of cellular senescence and its impact on aging. He explains how senolytic medicines could potentially treat age-related diseases like cancer and cardiovascular issues by targeting and eliminating senescent cells. Ned also shares insights on navigating biotechnology entrepreneurship, emphasizing the importance of calculated risks and innovative thinking in transforming ideas into successful companies.
AI Snips
Chapters
Transcript
Episode notes
Origins of Unity Biotechnology
- Ned David co-founded Unity Biotechnology after discussing longevity with Peter Attia for nearly a decade.
- They often discussed various scientific topics, including longevity.
Unity's Founding Team
- Ned David's co-founders include Jan van Deursen, Judy Campisi, and Daohang Zhou.
- They worked together at the Buck Institute to answer four key questions about senescence.
Risk Analysis in Company Creation
- Identify existential risks to your "beautiful, simple idea."
- Build work plans, budgets, and funding requests around systematically mitigating those risks.
